For the quarter ending 2025-09-30, LENZ has $210,704K in assets. $16,777K in debts. $25,399K in cash and cash equivalents.
| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 25,399 | 37,608 | ||
| Marketable securities | 176,773 | 171,911 | ||
| Inventory | 949 | - | ||
| Restricted cash | - | 114 | ||
| Prepaid expenses and other current assets | 3,876 | 3,969 | ||
| Restricted cash | 0 | 100 | ||
| Total current assets | 206,997 | 213,602 | ||
| Property and equipment, net | 1,258 | 1,169 | ||
| Operating lease right-of-use asset | 847 | 959 | ||
| Other assets | 1,602 | 1,602 | ||
| Total assets | 210,704 | 217,332 | ||
| Accounts payable | 4,323 | 2,854 | ||
| Accrued liabilities | 11,993 | 7,544 | ||
| Total current liabilities | 16,316 | 10,398 | ||
| Operating lease liability, net | 461 | 569 | ||
| Total liabilities | 16,777 | 10,967 | ||
| Common stock, par value of 0.00001 per share 300,000,000 shares authorized 28,588,261 and 27,531,490 shares issued at september30, 2025 and december31, 2024, respectively and 28,588,261 and 27,518,439 shares outstanding at september30, 2025 and december31, 2024, respectively | 1 | 1 | ||
| Additional paid-in capital | 384,944 | 380,871 | ||
| Accumulated deficit | -191,245 | -174,545 | ||
| Accumulated other comprehensive income | 227 | 38 | ||
| Total stockholders equity | 193,927 | 206,365 | ||
| Total liabilities and stockholders equity | 210,704 | 217,332 | ||
LENZ Therapeutics, Inc. (LENZ)
LENZ Therapeutics, Inc. (LENZ)